Is salivary evaluation of P53 and MMP-3 a good tool for early detection of oral squamous cell carcinoma?
Keywords:
OSCC, P53, MMP3, Saliva, ELISAAbstract
Objective: Oral squamous cell carcinoma is one of the most common malignancies around the world. Despite the advancement in treatment methods, the prognosis is still not good. Based on clinicians’ idea, the early diagnosis of the lesion can lead to better prognosis. Some salivary biomarkers such as matrix metalloproteinase-3 and P53 may detect OSCC in early stages. In this study we wanted to compare salivary MMP-3 and P53 levels in OSCC patients and control group.
Methods: Fifteen patients with OSCC (9 males and 6 females) were selected from oral pathology department, Babol, Iran. Salivary MMp-3 and P53 were measured by ELISA and compared with control group. Data was analyzed by ANOVA, T test, and Mann-Whitney.
Results: There was no significant differences between salivary MMP-3 and P53 concentration in patients with OSCC and healthy individuals.
Conclusion: Based on our findings and other similar studies, salivary MMP-3 and P53 levels might not be accurate enough to detect early stages of oral SCC. But there are controversial statements about these questions. So supplementary studies are needed to be done in future.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin .2011;61: 69–90.
2. Agha-Hosseini F, Mirzaii-Dizgah I, Farmanbar N, Abdollahi M. Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med.2012;41(10):736-740.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics,2010,CA a cancer J.Clin. 2010;60(5): 277-300.
4. Califano J, Van der Riet P, Westra W,et al . Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488–92.
5. Rosin MP, Cheng X, Poh C, et al . Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–62.
6. Sturgis EM, Wei Q. Genetic susceptibility–molecular epidemiology of head and neck cancer. Curr Opin Oncol .2002;14: 310–317.
7. Radhika T, Jeddy N, Nithya S, Muthumeenakshi R.M. Salivary biomarkers in oral squamous cell carcinoma-An insight.Journal of Oral Biology and Craniofacial Research.2016;6:551-554.
8. Kaufman E, Lamster IB. The diagnostic applications of saliva-A review.Crit Rev Oral Biol Med.2002;13(2):197-212.
9. Egeblad M. et al. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer.2002;2:161–174.
10. Chen Y, Zhang W, Geng N, Tian K, Jack Windsor L. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus. Head Neck 2008;30:1237-45.
11. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function and biochemistry. Circ Res 2003;92:827-39.
12. Liu SY, Liu YC, Huang WT, Huang GC, Su HJ, Lin MH. Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas. J Oral Pathol Med 2007; 36(7):430-435.
13. Varun BR, Nair BJ, Sivakumar TT, Joseph AP. Matrix metalloproteinases and their role in oral diseases: a review. Oral Maxillofac Pathol J 2012;3(1):186-191.
14. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004;10(6):311-318.
15. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, et al. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res.2010;16: 2022–2035.
16. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351(6326):453–6.
17. Lee JJ, Kuo MY, Cheng SJ, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(4):471-8.
18. Biramijamal F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res 2001; 61: 3119-3123.
19. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, et al. Meta-Analysis of MMP2, MMP3, andMMP9 Promoter Polymorphisms and Head and Neck Cancer Risk. PLoS ONE.2013; 8(4): e62023.
20. Stott-Miller M, Houck JR, Lohavanichbutr P, Méndez E, Upton MP, Futran ND, et al. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011;20(12):2628-2636.
21. Agha-Hosseini F, Mirzaii-Dizgah I, Mahboobi N, Shiorazian Sh, Harirchi I. Serum and Saliva MMP-3 in Patients with OLP and Oral SCC. The journal of Contemporary Dental Practice.Feb 2015;16(2):107-111.
22. Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR, Malekzadeh R. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol 2010; 16(39): 4958-4967.
23. Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T . P53 antibodies in the saliva of patients with squamous cell carci noma of the oral cavity. Int J Cancer.1998; 78:390-391.
24. Agha-Hosseini F, Mirzaii-Dizgah I, Miri-Zarandi NS. Unstimulated Salivary p53 in Patients with Oral Lichen Planus and Squamous Cell Carcinoma. Acta Medica Iranica.2015;53(7):439-443.
25. Schoelch ML, Regezi JA, Dekker NP, et al. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999;35(3):333-42.
26. Kuropkat C, Venkatesan TK, Caldarelli DD, et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx 2002;29(2):165-74.
27. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, et al. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control. 2009 April ; 20(3): 361–368.
2. Agha-Hosseini F, Mirzaii-Dizgah I, Farmanbar N, Abdollahi M. Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med.2012;41(10):736-740.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics,2010,CA a cancer J.Clin. 2010;60(5): 277-300.
4. Califano J, Van der Riet P, Westra W,et al . Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488–92.
5. Rosin MP, Cheng X, Poh C, et al . Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–62.
6. Sturgis EM, Wei Q. Genetic susceptibility–molecular epidemiology of head and neck cancer. Curr Opin Oncol .2002;14: 310–317.
7. Radhika T, Jeddy N, Nithya S, Muthumeenakshi R.M. Salivary biomarkers in oral squamous cell carcinoma-An insight.Journal of Oral Biology and Craniofacial Research.2016;6:551-554.
8. Kaufman E, Lamster IB. The diagnostic applications of saliva-A review.Crit Rev Oral Biol Med.2002;13(2):197-212.
9. Egeblad M. et al. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer.2002;2:161–174.
10. Chen Y, Zhang W, Geng N, Tian K, Jack Windsor L. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus. Head Neck 2008;30:1237-45.
11. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function and biochemistry. Circ Res 2003;92:827-39.
12. Liu SY, Liu YC, Huang WT, Huang GC, Su HJ, Lin MH. Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas. J Oral Pathol Med 2007; 36(7):430-435.
13. Varun BR, Nair BJ, Sivakumar TT, Joseph AP. Matrix metalloproteinases and their role in oral diseases: a review. Oral Maxillofac Pathol J 2012;3(1):186-191.
14. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004;10(6):311-318.
15. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, et al. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res.2010;16: 2022–2035.
16. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351(6326):453–6.
17. Lee JJ, Kuo MY, Cheng SJ, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(4):471-8.
18. Biramijamal F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res 2001; 61: 3119-3123.
19. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, et al. Meta-Analysis of MMP2, MMP3, andMMP9 Promoter Polymorphisms and Head and Neck Cancer Risk. PLoS ONE.2013; 8(4): e62023.
20. Stott-Miller M, Houck JR, Lohavanichbutr P, Méndez E, Upton MP, Futran ND, et al. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011;20(12):2628-2636.
21. Agha-Hosseini F, Mirzaii-Dizgah I, Mahboobi N, Shiorazian Sh, Harirchi I. Serum and Saliva MMP-3 in Patients with OLP and Oral SCC. The journal of Contemporary Dental Practice.Feb 2015;16(2):107-111.
22. Taghavi N, Biramijamal F, Sotoudeh M, Moaven O, Khademi H, Abbaszadegan MR, Malekzadeh R. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. World J Gastroenterol 2010; 16(39): 4958-4967.
23. Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T . P53 antibodies in the saliva of patients with squamous cell carci noma of the oral cavity. Int J Cancer.1998; 78:390-391.
24. Agha-Hosseini F, Mirzaii-Dizgah I, Miri-Zarandi NS. Unstimulated Salivary p53 in Patients with Oral Lichen Planus and Squamous Cell Carcinoma. Acta Medica Iranica.2015;53(7):439-443.
25. Schoelch ML, Regezi JA, Dekker NP, et al. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999;35(3):333-42.
26. Kuropkat C, Venkatesan TK, Caldarelli DD, et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx 2002;29(2):165-74.
27. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, et al. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control. 2009 April ; 20(3): 361–368.
Downloads
Published
2018-09-26
How to Cite
Nafarzadeh, S., emamgholipour, mohsen, Bijani, F., Hosseinkazemi, H., Mostafazadeh, A., Khakbaz, O., … Khafri, S. (2018). Is salivary evaluation of P53 and MMP-3 a good tool for early detection of oral squamous cell carcinoma?. Journal of Contemporary Medical Sciences, 4(3). Retrieved from https://jocms.org/index.php/jcms/article/view/398
Issue
Section
Short Communication
